The ratio of fat-mass loss to lean-mass loss was similar to that reported in lifestyle-based intervention in the Look AHEAD trial (241) and surgical treatment for obesity (242)
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
That does not make the topic meaningless, but it does mean claims should be careful
Space alcohol and your injection by at least 24 hours when possible to minimize overlapping GI stress